# Anlotinib Treatment in Steroid Depenent/Refractory cGVHD

> **NCT04232397** · PHASE2 · TERMINATED · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 5 (actual)

## Conditions studied

- Chronic Graft-versus-host-disease

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04232397
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-10
- **Primary completion:** 2020-09-15
- **Final completion:** 2021-03-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** the efficency is not good enough to enroll more patients
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04232397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04232397, "Anlotinib Treatment in Steroid Depenent/Refractory cGVHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04232397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*